Research Paper Volume 12, Issue 5 pp 4641—4659

Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models

Figure 2. MTS assay of cells treated with different concentration of SLAB51 (left). MTS assay of cells treated with 35 μM 6-OHDA and 35 μM 6-OHDA and SLAB51 0.1mg/ml (right). Data are mean ± SE of three different experiments run in quadruplicate (n=3). *** p< 0.0005 vs Ctr; +++ p< 0.0005 vs 6-OHDA.